<DOC>
	<DOCNO>NCT00142038</DOCNO>
	<brief_summary>Up date worldwide accept standard chemotherapy 1st-line treatment advance metastatic gastric cancer.A combination epirubicin , cisplatin 5-FU ( ECF ) best examine combination widely use . Recent study ( Thuss-Patience et al , J. Clin . Oncol . 2005 ) could show combination docetaxel 5-FU might similarly effective ECF . 5-FU docetaxel +/- cisplatin combination investigate many group may future reference treatment . Many data suggest 5-FU infusion replace oral capecitabine equal efficacy . As docetaxel/5-FU probably similarly effective epirubicin/cisplatin/5-FU replacement 5-FU infusion capecitabine make chemotherapy comfortable patient investigate study chemotherapy docetaxel capecitabine 1st-line therapy metastatic advance gastric cancer .</brief_summary>
	<brief_title>Docetaxel Capecitabine Advanced Gastric Cancer</brief_title>
	<detailed_description>Patients locally advance metastatic gastric adenocarcinoma receive prior chemotherapy advance disease enrol study . Patients treat oral capecitabine 1000mg/sqm twice per day day 1-14 docetaxel 75 mg/sqm day 1 1 hour i.v . infusion . chemotherapy repeat every 21 day . Staging image perform every 2 cycle . After 40 include patient amendment do start chemotherapy reduce improve tolerability . Starting dose docetaxel amend 60 mg/sqm , d1 , start dose capecitabine reduce 800 mg/sqm twice per day , d1-14 . The patient number include increase 70 pt . Therapy continue tumor progression maximum 10 cycle . Therapy stop case severe side effect , tumor progression withdrawal consent . This investigator initiate study support Hoffmann-La Roche Sanofi-Aventis .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients histologically proven adenocarcinoma stomach GEjunction . Patients distant metastasis patient locally advanced disease curatively operable proven laparoscopy patient recurrence gastrectomy . Patients receive prior palliative chemotherapy . An adjuvant chemotherapy allow . Age 18 75 year . Sufficient bone marrow function define leucocyte &gt; 3.0 Gpt/l , thrombocytes &gt; 100 Gpt/l Sufficient liver function define bilirubin &lt; 1.5 mg/dl ( 1.5 x ULN ) , ALT AST &lt; 3 x ULN . Sufficient renal function define serum creatinine &lt; 1.25 x ULN , creatinine clearance &gt; 60 ml/min calculate accord CockroftGault Contraception patient reproductive potential . Karnofskyperformanceindex least 60 % Measurable tumor lesion . Written informed consent patient . Karnofskyperformanceindex less equal 50 % . Patients already receive palliative firstline chemotherapy . Prior second malignancy , except basal cell carcinoma skin curatively treat carcinoma situ cervix . Parallel radiation therapy Uncontrolled infection . CNSmetastasis Other severe medical disease Prior major surgery le 2 week Parallel treatment experimental therapy . Parallel treatment therapy aim tumor . Chronic diarrhea , subileus . Chronic inflammatory bowel disease intestinal obstruction . Unable take oral medication . Pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>docetaxel</keyword>
	<keyword>capecitabine</keyword>
</DOC>